A Multicenter, Double-blind, Randomised, Parallel Group, Placebo-controlled Phase III Study of the Efficacy and Safety of Quetiapine Fumarate Sustained Release (Seroquel SR) as Mono-therapy in the Treatment of Elderly Patients with Generalised Anxiety Disorder (CHROMIUM Study).

Trial Profile

A Multicenter, Double-blind, Randomised, Parallel Group, Placebo-controlled Phase III Study of the Efficacy and Safety of Quetiapine Fumarate Sustained Release (Seroquel SR) as Mono-therapy in the Treatment of Elderly Patients with Generalised Anxiety Disorder (CHROMIUM Study).

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Jun 2013

At a glance

  • Drugs Quetiapine (Primary)
  • Indications Generalised anxiety disorder
  • Focus Registrational; Therapeutic Use
  • Acronyms CHROMIUM
  • Sponsors AstraZeneca
  • Most Recent Events

    • 12 Jul 2011 New source identified and integrated (European Clinical Trials Database, EudraCT2006-001195-21).
    • 22 May 2010 Results have been presented at the 163rd Annual Meeting of the American Psychiatric Association (APA).
    • 28 Jun 2009 Results have been presented at the 9th World Congress of Biological Psychiatry
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top